Farxiga Cost in New Mexico 2026: Cash Price, Medicaid Coverage, and Your Cheapest Legal Options

What Does Farxiga Actually Cost in New Mexico in 2026?

The retail cash price for a 30-tablet supply of Farxiga 10 mg in New Mexico sits at approximately $620 per month in 2026, matching AstraZeneca's published list price. That figure is consistent across major chains such as Walgreens, CVS, and Walmart in Albuquerque and Santa Fe. Without insurance or a savings program, most patients pay close to the full list price because generic dapagliflozin is not yet available in the United States.

AstraZeneca set the Farxiga list price at $620/month, a number that has remained stable through early 2026. GoodRx and similar coupon platforms sometimes reduce that to $580 to $600 at select pharmacies, but the savings are modest compared with manufacturer or compounded pathways. The drug is dosed once daily, so a single 30-count bottle covers one full month. Patients prescribed the 5 mg dose for chronic kidney disease (CKD) titration use the same bottle count but at a different per-tablet cost that pharmacies price separately.

For context, dapagliflozin's clinical weight is real. DAPA-HF (N=4,744) showed that dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% vs. placebo (hazard ratio 0.74 to 95% CI 0.65 to 0.85, P<0.001) in patients with heart failure with reduced ejection fraction [1]. That outcome profile is why cardiologists and nephrologists frequently prescribe it, and why cost becomes such a material barrier when patients cannot access coverage.

Does New Mexico Medicaid Cover Farxiga?

New Mexico Medicaid does not cover Farxiga for any of its three FDA-approved indications (type 2 diabetes, heart failure, or CKD) as of mid-2025. The state's Medicaid preferred drug list (PDL) for SGLT2 inhibitors does not include dapagliflozin as a covered agent, which means prior authorization requests are routinely denied rather than reviewed on individual clinical merit.

This is a significant gap. New Mexico has one of the highest rates of diabetes-related mortality in the Southwest, and SGLT2 inhibitors carry strong guideline endorsement. The American Diabetes Association's 2024 Standards of Care state that SGLT2 inhibitors "should be considered for patients with type 2 diabetes and established cardiovascular disease, CKD, or heart failure to reduce cardiovascular and kidney-related risk" [2]. That guideline language has not translated into Medicaid formulary inclusion in New Mexico.

Patients enrolled in Centennial Care (New Mexico's Medicaid managed care program) through carriers such as Molina Healthcare of New Mexico, Presbyterian Salud!, or Western Sky Community Care should call the pharmacy benefits line on their member card to confirm current formulary status. Formularies can change quarterly, and a motivated prescriber can sometimes submit a medical exception request supported by DAPA-HF or DAPA-CKD trial data.

DAPA-CKD (N=4,304) showed dapagliflozin reduced the composite kidney or cardiovascular endpoint by 39% vs. placebo (HR 0.61 to 95% CI 0.51 to 0.72, P<0.001) in patients with CKD stages 2 to 4 [3]. That magnitude of benefit may support a compelling medical necessity letter to a Medicaid plan.

Which Private Insurance Plans Cover Farxiga in New Mexico?

Coverage varies widely by plan tier and employer. Most large commercial plans sold through New Mexico's beWellnm exchange or employer groups place Farxiga on Tier 3 (preferred brand) with copays ranging from $40 to $120 per month after deductible. Some plans moved dapagliflozin to Tier 2 after AstraZeneca negotiated rebate agreements, so your actual copay depends on your specific formulary year.

Blue Cross Blue Shield of New Mexico, Presbyterian Health Plan, and Molina Healthcare commercial (not Medicaid) plans each carry Farxiga on their 2026 formularies, though prior authorization is required for the heart failure and CKD indications at some of these carriers. The PA typically asks for documentation of an echocardiogram confirming ejection fraction <45% (for HFrEF indication) or an eGFR and urine albumin-to-creatinine ratio for the CKD indication.

Patients on Medicare Part D in New Mexico should check their specific plan's formulary through the Medicare Plan Finder tool. Farxiga is covered on many Part D plans as a Tier 3 or Tier 4 agent, and cost sharing after the Inflation Reduction Act's $2,000 out-of-pocket cap (effective 2025) meaningfully reduces annual burden for high-utilization patients.

How Does the AstraZeneca Savings Card Work in New Mexico?

Commercially insured patients in New Mexico who qualify can pay as little as $0 per month through AstraZeneca's Farxiga Savings Card. The program is available to patients with private insurance who meet income and enrollment criteria. AstraZeneca caps the savings card benefit at a defined annual maximum, so patients should enroll early in the calendar year to maximize coverage.

The savings card does not work for patients covered by any federal or state government program, including Medicare, Medicaid, TRICARE, or the Veterans Administration. That exclusion leaves a large portion of New Mexico's lower-income and older population outside the program's reach, since New Mexico has one of the highest Medicaid enrollment rates in the country (approximately 40% of the state's population as of 2024) [4].

To enroll, patients visit AstraZeneca's official patient support site or ask their prescriber's office to provide a co-pay card at the time of prescribing. The card is processed at the pharmacy like a secondary insurance and typically requires no prior approval beyond confirming commercial insurance status.

Is Compounded Dapagliflozin Legal in New Mexico?

Compounded dapagliflozin is legally available in New Mexico through state-licensed 503A compounding pharmacies. A 503A pharmacy compounds medications for individual patients based on a valid prescription from a licensed prescriber. The compound is not FDA-approved as a finished product, but the active pharmaceutical ingredient (API) itself can be compounded when a prescriber determines it is medically appropriate for a specific patient.

The legal framework matters here. Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies. A 503B outsourcing facility, by contrast, can compound in bulk but is subject to stricter FDA oversight and currently cannot compound dapagliflozin without a shortage or clinical need designation. In New Mexico, 503A compounding is regulated jointly by the New Mexico Board of Pharmacy and federal law.

Pricing for compounded dapagliflozin varies by pharmacy and formulation, but some 503A pharmacies in New Mexico and those shipping to NM residents charge substantially less than the $620 brand-name list price. Some telehealth platforms that partner with 503A pharmacies price compounded dapagliflozin at well below $100 per month for patients paying cash.

A practical framework for deciding between brand Farxiga and compounded dapagliflozin in New Mexico:

1. Commercially insured patients: Apply for the AstraZeneca Savings Card first. If your out-of-pocket cost falls to $0 or <$30/month, the brand product makes sense because it is FDA-approved and bioequivalence is guaranteed.
2. Medicaid patients: New Mexico Medicaid does not cover Farxiga. Request a medical exception with supporting trial data (DAPA-HF, DAPA-CKD). If denied, a 503A compounded option may be the most affordable legal pathway.
3. Uninsured or underinsured patients: Compare GoodRx pricing at local NM pharmacies against 503A compounded pricing. GoodRx rarely brings Farxiga below $580; a reputable 503A compound can cost less for many patients.
4. Medicare Part D patients: Check your plan's formulary and apply the IRA's $2,000 annual cap. Do not use AstraZeneca's savings card (it is ineligible). If your plan does not cover Farxiga, ask your prescriber about switching to empagliflozin or canagliflozin, which may be on your plan's formulary with similar cardiovascular outcome data.

Quality control is the primary clinical consideration with compounded products. Patients should ask any 503A pharmacy for a certificate of analysis (CoA) confirming the API purity and concentration before dispensing. A reputable compounding pharmacy will provide this without hesitation.

Can I Get Farxiga via Telehealth in New Mexico?

Telehealth prescribing of Farxiga is legal and available to New Mexico residents. A licensed prescriber in New Mexico (or a clinician licensed in another state with a valid interstate practice agreement) can prescribe dapagliflozin after a synchronous audio-video visit that meets state telehealth standards. New Mexico's telehealth rules, codified under the New Mexico Telehealth Act, do not require an in-person visit prior to initiating a chronic disease medication like dapagliflozin when the clinical evaluation is adequate via telemedicine.

Several HealthRX-affiliated clinicians hold New Mexico licensure and can evaluate patients for Farxiga or compounded dapagliflozin within a single telehealth visit. The visit typically covers:

• Review of baseline HbA1c or eGFR and urine ACR (labs can be ordered to a local draw site before the visit)
• Blood pressure and renal function assessment
• Contraindication screening (eGFR <25 mL/min/1.73m², active genital mycotic infection history, recurrent DKA)
• Confirmation of indication (T2D, HFrEF, or CKD)

After the visit, the prescription is sent electronically to the patient's preferred pharmacy or to a partnered 503A compounding pharmacy depending on the patient's insurance and cost situation.

The FDA approved Farxiga for type 2 diabetes in January 2014, for heart failure with reduced ejection fraction in May 2020, and for CKD in April 2021 [5]. Each indication has a slightly different dosing and monitoring protocol, which the telehealth visit should address specifically.

What Are the Clinical Reasons Farxiga Is Worth the Cost for Many Patients?

For patients who can access it affordably, dapagliflozin's outcomes data across three major conditions make it one of the most well-supported agents in modern cardio-nephrology.

In type 2 diabetes, the DECLARE-TIMI 58 trial (N=17,160) showed dapagliflozin reduced the rate of hospitalization for heart failure or cardiovascular death by 17% vs. placebo (HR 0.83 to 95% CI 0.73 to 0.95, P=0.005) [6]. That was in a broad population that included patients with multiple cardiovascular risk factors but not necessarily established disease, which broadened the prescribing rationale significantly.

The DAPA-CKD trial extended this to patients with CKD even in the absence of diabetes. About one-third of DAPA-CKD participants did not have type 2 diabetes, yet the benefit on kidney and cardiovascular endpoints was consistent across both subgroups [3]. The FDA's 2021 CKD approval was based on this data, making dapagliflozin the first SGLT2 inhibitor with a CKD indication in non-diabetic patients.

In heart failure, DAPA-HF's result (26% reduction in the primary composite endpoint) remained strong across subgroups defined by age, sex, and background therapy, including patients already receiving sacubitril/valsartan (Entresto) [1]. The 2022 AHA/ACC heart failure guidelines give SGLT2 inhibitors a Class I, Level of Evidence A recommendation for patients with HFrEF to reduce heart failure hospitalizations and cardiovascular mortality [7].

"SGLT2 inhibitors have become a cornerstone of heart failure therapy with reduced ejection fraction," according to the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure, "and should be prescribed in the absence of contraindications regardless of the presence of type 2 diabetes" [7].

The cost-effectiveness argument is real. A 2021 analysis in the Journal of the American College of Cardiology estimated that dapagliflozin in HFrEF cost approximately $53,000 per quality-adjusted life year (QALY) gained at U.S. list price, well below the conventional $100,000/QALY threshold [8]. For New Mexico patients without coverage, closing that gap requires accessing the drug through savings programs or compounded alternatives.

What Safety Monitoring Does a New Mexico Patient Need?

Starting dapagliflozin requires a baseline metabolic panel. Specifically, an eGFR below 25 mL/min/1.73m² is a contraindication for the type 2 diabetes indication, though the drug can be initiated for CKD down to eGFR <25 in some protocols under close nephrology guidance. Patients should have eGFR confirmed before initiating and rechecked at 3 months.

Genital mycotic infections (yeast infections in women, balanitis in uncircumcised men) occur in roughly 6 to 8% of patients during the first 6 months and are the most common side effect requiring management. Most cases resolve with a single-dose antifungal. Diabetic ketoacidosis (DKA) is rare but can occur at blood glucose levels that appear deceptively normal (euglycemic DKA), particularly in patients who have been fasting, are undergoing surgery, or are on a very-low-carbohydrate diet. Patients should hold dapagliflozin at least 3 days before any planned procedure requiring general anesthesia.

Urinary tract infections, volume depletion in patients on loop diuretics, and a small (~3 to 4 mmHg) reduction in systolic blood pressure are additional effects that the prescribing clinician should review at the first follow-up visit, typically 4 to 8 weeks after initiation.

Comparing Dapagliflozin to Other SGLT2 Inhibitors Available in New Mexico

Dapagliflozin (Farxiga) is not the only SGLT2 inhibitor with a strong outcomes profile. New Mexico patients whose insurance does not cover Farxiga may find that empagliflozin (Jardiance) or canagliflozin (Invokana) are on their plan's formulary at a lower tier.

Empagliflozin's EMPEROR-Reduced trial (N=3,730) produced a 25% reduction in the primary cardiovascular composite (HR 0.75, P<0.001), comparable to DAPA-HF [9]. Canagliflozin's CREDENCE trial (N=4,401) showed a 30% reduction in the kidney composite endpoint in type 2 diabetes with CKD [10]. These agents are not interchangeable in terms of FDA labeling, but a cardiologist or nephrologist may consider substituting one for another based on formulary availability when the clinical indication is substantially overlapping.

New Mexico patients should ask their prescriber explicitly: "Is there an SGLT2 inhibitor on my plan's formulary that covers my indication?" A formulary substitution may resolve the cost problem without requiring a savings program or compounding pathway.